Introduction
Glaucoma is defined to be a progressive optic neuropathy that can lead to irreversible blindness. There are various known risk factors for glaucoma. However, intraocular pressure (IOP) appears to be the only known modifiable risk factor for control of the onset and progression of optic neuropathy.[1] Besides the medical and surgical therapy for glaucoma, laser treatment has received considerable attention as an effective modality in recent times. Laser trabeculoplasty commonly practiced are argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT) to increase aqueous humor outflow and thus lower intraocular pressure.[2]
Wise and Witter described the first protocol for ALT in 1979. They demonstrated the safety and efficacy of ALT in a group of patients with open-angle glaucoma (OAG). ALT's safety and long-term efficacy were studied in the glaucoma laser trial. In the glaucoma laser trial, eyes receiving 360° ALT were compared with medical monotherapy with a follow-up period of 2.5 to 5.5 years, concluding that trabeculoplasty was as efficacious as medical therapy in reducing intraocular pressure. However, ALT did not become primary therapy in patients with primary open-angle glaucoma (POAG) because of reduced efficacy over time, so it was used as an adjunctive therapy. Laser trabeculoplasty gained popularity with SLT. SLT uses a Q-switched frequency-doubled Nd: YAG laser in the trabecular meshwork, which appears less destructive than ALT. However, it has been noticed that both ALT and SLT are equally efficacious in reducing intraocular pressure in OAG.
Anatomy and Physiology
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Anatomy and Physiology
Anatomy of Angle of the Anterior Chamber
Clinically, the structures are visualized by gonioscopic examination. The structures forming the angle of the anterior chamber are as follows (posterior to anterior):
- Ciliary Body Band
- It is formed by the anterior-most part of the ciliary body between its attachment to the scleral spur and iris insertion.
- It appears to be a grey or dark brown band
- on the gonioscopy. It is the most posterior landmark.
- Scleral Spur
- This posterior part of the scleral sulcus is related to the ciliary body posteriorly and corneoscleral meshwork anteriorly.
- It appears as a white band on the gonioscopy.
- Trabecular Meshwork
- It appears as a band anterior to the scleral spur. It has 2 clinical parts: anterior non-pigmented and posterior pigmented. The posterior is the draining part; hence, it is pigmented.
- It is responsible for 90% of the aqueous humor outflow.
- It has 3 components:
- The uveal meshwork: the innermost portion consists of cord-like endothelial cells, and the intertrabecular spaces are relatively large, around 70 microns in diameter, offering little resistance to the passage of aqueous matter.
- The corneoscleral meshwork: lies anterior to the uveal meshwork and forms the thickest portion of the trabecular meshwork. The intertrabecular spaces are lesser, around 35 microns, offering greater resistance.
- The juxtacanalicular meshwork: the outer part of the trabecular meshwork, lines the endothelium of the Schelmm canal. The intertrabecular spaces are around 7 microns, offering maximum resistance to aqueous outflow.
- Schwalbe Line
- It appears as a fine ridge just in front of the trabecular meshwork, formed by the prominent end of the Descemet membrane of the cornea.
- It marks the anterior limit of the structures forming the angle of the anterior chamber.[3]
Physiological Aspects of Outflow
The aqueous humor flows from the posterior chamber via the pupil in the anterior chamber. It exits the anterior chamber via the following routes:
- Trabecular meshwork - about 90% of aqueous flows through this route
- Uveoscleral pathway - about 10% of aqueous flows via the uveoscleral pathway
- Iris - some aqueous fluids also drain via the iris
Indications
Indications for laser trabeculoplasty include:
- In patients with OAG, uncontrolled by medical therapy, the IOP remains above the target IOP despite the maximum medical therapy that can be tolerated.[4]
- In patients with OAG with poor compliance to medical treatment, the IOP remains above the target IOP, and the glaucomatous optic atrophy worsens.
- Patients with OAG with poor tolerance to medical therapy
- Patients with pseudoexfoliation or pigmentary glaucomas
- Angle-closure glaucoma with a patent iridotomy
- When the glaucoma surgery needs to be deferred or delayed
Contraindications
Contraindications for laser trabeculoplasty inclue:
- Inflammatory glaucoma: post-laser inflammations will increase, leading to further IOP spikes
- Advanced glaucoma
- Poor visualization of the TM is due to synechiae, as the site of action is trabecular meshwork
Equipment
Laser System
- Argon green laser light is used in ALT
- Q-switched Nd: YAG laser is used in SLT
Lenses used: A contact lens with a mirror to visualize the anterior chamber angle (gonioprism) is used in laser trabeculoplasty. The lens should have an anti-reflective coating on its front surface.
- Goldmann type 3-mirror lens has 1 mirror inclined at an angle of 59°.
- Thorpe 4-mirror gonioscopy lens has all the mirrors are inclined at 62°. It has the advantage of simultaneous viewing of all the quadrants of the angle of the anterior chamber.
- Ritch trabeculoplasty lens has 2 mirrors are inclined at 59° to view the inferior quadrants and 2 at 64° to view the superior angles. It has a 17 diopter planoconvex lens which provides a magnification of 1.4, thus reducing a laser spot size.
- Latina lens- this lens is designed explicitly for SLT. It has a single mirror at a 63° angle. It has a magnification of 1.
Personnel
The team performing a laser trabeculoplasty may include:
- Attending and resident surgeons
- Nursing staff
- Operative room technicians
Preparation
History
A thorough medical and ocular history should be taken.
Examination
The preoperative examination must include:
- Gonioscopic examination of the angle of the anterior chamber- visibility of trabecular meshwork without indentation is noted as this is the target structure for trabeculoplasty. If the iris approach is steep, but the trabecular meshwork is visible by asking the patient to look towards the mirror, this implies sufficient angle area is available for treatment. Any synechiae should be ruled out because it will obstruct access to the trabecular meshwork, hence a contraindication to the procedure. The degree of pigmentation of the trabecular meshwork should be noted because it will influence the initial energy level chosen for the procedure.[5][6]
- Intraocular pressure measurement- to record a baseline IOP before the procedure.
- Central corneal thickness
- Optic nerve evaluation using slit-lamp biomicroscopy for glaucomatous damage
- Visual field charting
Medications
- IOP lowering agents- either apraclonidine or brimonidine, both being alpha-adrenergic agonists. It decreases the chance of an IOP spike in the immediate post-op period.[7]
- Topical anesthetic agents –immediately before the procedure to anesthetize the eye.
Informed consent should be obtained before the procedure. The patient should understand all the risks, benefits, and alternatives to the procedure. Managing the expectations and addressing questions about the patient's procedure is essential. Also, the possibility of failure of the procedure should be explained.
Technique or Treatment
Mechanism Of Action
Several theories have been proposed, and the mechanism is as follows:
- Cellular - suggests that the reduction in IOP occurs due to the cellular activity stimulated by the laser; there is increased recruitment of macrophages in the trabecular meshwork, which aids in remodeling the extracellular matrix, thus allowing for increased aqueous outflow.
- Cytokine production- there is increased expression and secretion of IL-1 beta and TNF alpha in the first 8 hours after treatment; these mediate increased trabecular stromelysin expression, which leads to remodeling of the juxtacanalicular extracellular matrix of the trabecular meshwork. This improves the normal outflow facility, thereby decreasing IOP.
- The increased conductivity of the Schlemm canal- SLT leads to a 3-fold increase in Schlemm canal cells conductivity, thus increasing the transendothelial fluid flow across Schlemm canal cells.
- ALT- causes coagulative necrosis of the trabecular meshwork.
- SLT- causes cracking of intracytoplasmic pigment granules and disruption of the endothelial cells of the trabecular meshwork
Technique
|
Argon Laser Trabeculoplasty |
Selective Laser Trabeculoplasty |
Laser type |
Argon green laser |
Frequency-doubled Nd: YAG laser |
Duration |
0.1 second |
3 ns |
Spot size |
50 microns |
400 microns |
Power |
300 - 1000 mW, depending on the response |
0.8 – 1 mJ in lightly pigmented angles, 0.3 – 0.6 mJ in heavily pigmented angles. |
Target |
Junction of anterior non-pigmented and posterior pigmented trabecular meshwork |
Pigmented trabecular meshwork |
End Point |
Blanching of trabecular meshwork or appearance of a tiny bubble |
The appearance of small bubbles closer to the trabecular meshwork |
The extent of angle treated |
Treating 360° in 1 sitting is associated with IOP spikes; hence, 180° of the angle is treated first - further treatment is decided based on the initial response |
180° or 360° can be treated in a single session [8] |
Complications
The complications that can manifest with laser trabeculoplasty are as follows:
- IOP rise - the most common complication in patients undergoing laser trabeculoplasty. The frequency of IOP spikes can be reduced by two-thirds using prophylactic alpha-adrenergic agonists about 30-60 minutes before the procedure.[9] A severe and frequent IOP rise occurs with:
- The use of higher energy levels,
- 360° angle treatments,
- Posterior placement of laser beam,
- Heavy pigmentation of the angle
- A low aqueous outflow facility. These IOP spikes are usually transient, occur in the first hour, and resolve with medical treatment. However, in cases with sustained IOP rise, surgical management is needed.[10]
- Low-grade iritis
- Formation of PAS
- Corneal edema- occurs due to HSV reactivation. The inflammatory cascade following laser therapy reactivates the virus.
- Hyphema
Clinical Significance
The effect of either type of laser trabeculoplasty decreases gradually over time. A prospective study that randomized patients to 180° of SLT versus ALT, did not find any statistically significant difference in IOP lowering between the 2 types of laser trabeculoplasty. The effect of trabeculoplasty on the diurnal curve shows that both ALT and SLT decrease diurnal IOP fluctuation. In different subgroups of patients of POAG, both ALT and SLT have been found efficacious compared to medical treatment. In pseudoexfoliation glaucoma, SLT is equally efficacious in pseudophakic eyes compared to phakic ones, whereas ALT is generally performed in phakic eyes. Laser trabeculoplasty is a cost-effective procedure that can be performed as an adjunct to medical therapy or to control IOP when the surgical treatment is delayed. It is gaining popularity as a primary mode of treatment in several OAG patients.[11][12]
Enhancing Healthcare Team Outcomes
Glaucoma leads to irreversible damage to the optic nerve, thus vision, which can adversely impact a person's life personally and socially. Hence, an interprofessional approach should be adopted to identify, treat, and delay glaucoma progression. The clinician should carefully examine to uncover early signs of glaucoma. If found, appropriate steps should be adopted. A physician in the periphery should refer the patient to a higher center for management. Patient counseling plays an important role. A combined effort by the treating doctor, nurses, and pharmacist should explain the necessity of seeking early treatment. The importance of medication compliance should also be presented. Family members of a patient diagnosed with glaucoma should be encouraged to get themselves screened. Patients undergoing laser procedures should understand the importance of the procedure and any potential complications. Any misconception regarding the laser procedure should be clarified, and the patient should receive an explanation regarding the safety and efficacy of the procedure. An interprofessional approach is key to addressing the global burden of glaucoma. There should be cooperation at each level to prevent the attack by glaucoma.
References
Meier-Gibbons F, Töteberg-Harms M. [Structure/function/treatment in glaucoma: progress over the last 10 years]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2021 Dec:118(12):1216-1221. doi: 10.1007/s00347-021-01505-2. Epub 2021 Oct 5 [PubMed PMID: 34609610]
Congdon N,Azuara-Blanco A,Solberg Y,Traverso CE,Iester M,Cutolo CA,Bagnis A,Aung T,Fudemberg SJ,Lindstrom R,Samuelson T,Singh K,Blumenthal EZ,Gazzard G,GLAUrious study group., Direct selective laser trabeculoplasty in open angle glaucoma study design: a multicentre, randomised, controlled, investigator-masked trial (GLAUrious). The British journal of ophthalmology. 2021 Aug 25; [PubMed PMID: 34433548]
Level 1 (high-level) evidenceKagemann L,Wollstein G,Ishikawa H,Sigal IA,Folio LS,Xu J,Gong H,Schuman JS, 3D visualization of aqueous humor outflow structures in-situ in humans. Experimental eye research. 2011 Sep; [PubMed PMID: 21514296]
Level 2 (mid-level) evidenceLee JH, Na JH, Chung HJ, Choi JY, Kim MJ. Selective Laser Trabeculoplasty for Medically Uncontrolled Pseudoexfoliation Glaucoma in Korean Patients. Korean journal of ophthalmology : KJO. 2021 Dec:35(6):476-483. doi: 10.3341/kjo.2021.0086. Epub 2021 Oct 12 [PubMed PMID: 34634862]
Barão R,Cutolo C,Tanito M,Hommer A,Faschinger C,Abegão Pinto L,Traverso C, Agreement Analysis on Angle Characteristics with Automated Gonioscopy. Journal of glaucoma. 2021 Sep 23; [PubMed PMID: 34559700]
Brusini P, Global Glaucoma Staging System (GGSS): A New Method to Simultaneously Assess the Severity of Both Functional and Structural Damage in Glaucoma. Journal of clinical medicine. 2021 Sep 26; [PubMed PMID: 34640431]
Yan J, Xiong X, Shen J, Huang T. The use of fixed dose drug combinations for glaucoma in clinical settings: a retrospective, observational, single-centre study. International ophthalmology. 2022 Mar:42(3):945-950. doi: 10.1007/s10792-021-02076-6. Epub 2021 Oct 12 [PubMed PMID: 34635957]
Level 2 (mid-level) evidenceWang H, Cheng JW, Wei RL, Cai JP, Li Y, Ma XY. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2013 Jun:48(3):186-92. doi: 10.1016/j.jcjo.2013.01.001. Epub [PubMed PMID: 23769780]
Level 1 (high-level) evidenceZhang L,Weizer JS,Musch DC, Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. The Cochrane database of systematic reviews. 2017 Feb 23; [PubMed PMID: 28231380]
Level 1 (high-level) evidenceThrane VR,Thrane AS,Bergo C,Halvorsen H,Krohn J, Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty. Journal of glaucoma. 2020 Apr; [PubMed PMID: 32053556]
Lowry EA,Greninger DA,Porco TC,Naseri A,Stamper RL,Han Y, A Comparison of Resident-performed Argon and Selective Laser Trabeculoplasty in Patients With Open-angle Glaucoma. Journal of glaucoma. 2016 Mar; [PubMed PMID: 25651207]
Level 2 (mid-level) evidenceBovell AM, Damji KF, Hodge WG, Rock WJ, Buhrmann RR, Pan YI. Long term effects on the lowering of intraocular pressure: selective laser or argon laser trabeculoplasty? Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2011 Oct:46(5):408-13. doi: 10.1016/j.jcjo.2011.07.016. Epub 2011 Aug 4 [PubMed PMID: 21995983]
Level 1 (high-level) evidence